Table 2. In Vivo Efficacy and Terminal Plasma Concentrations of 8a and Flubendazole^a.

					drug concentration (μM)
in vivo model	drug treatment	worm count median ± SEM (range)	adult worm reduction/animals with no worms	P ≤	24 h after last dose	interim	necropsy
B. malayi; necropsy on day 42	vehicle (SC study), n = 5	12 ± 0.73 (11–15)			N/A	N/A	N/A
	flubendazole, 10 mg/kg × 5 days, QD, SC, n = 10	0 ± 0 (0–0)	100%/100%	0.0001	0.173	NM	0.043
	8a, 150 mg/kg × 14 days, QD, SC (solution), n = 6	2 ± 2.14 (0–12)	83.3%/50%	0.0622	2.47	0.07 (day 28)	0.01
	8a, 100 mg/kg × 14 days, QD, SC (suspension), n = 16	0 ± 0.19 (0–3)	100%/87.5%	0.0001	4.10	5.36 (day 28)	3.38
	vehicle (PO study), n = 5	8 ± 0.81 (5–10)			N/A	N/A	N/A
	8a, 100 mg/kg × 28 days, QD, PO (suspension), n = 10	7 ± 1.38 (4–16)	12.5%/0%	0.9999	0.128	NM	<LOQ
B. pahangi; necropsy on day 63; n = 5 per group	vehicle	89 ± 12.79 (64–146)			N/A	N/A	N/A
	flubendazole, 10 mg/kg × 5 days, QD, SC	0 ± 0 (0–0)	100%/100%	0.0009	0.178	NM	0.018
	8a, 100 mg/kg × 14 days, QD, SC (suspension)	0 ± 0.333 (0–2)	100%/83%	0.0024	5.87	NM	1.15
	8a, 100 mg/kg × 28 days, QD, PO (suspension)	67.5 ± 14.86 (2–114)	24%/0%	0.9999	0.13	NM	<LOQ
L. sigmodontis; necropsy on day 63; n = 4 vehicle; n = 6 other groups	vehicle	8.5 ± 3.28 (5–20)			N/A		N/A
	flubendazole, 10 mg/kg × 5 days, QD, SC	0 ± 0 (0–0)	100%/100%	0.0208	0.283	NM	0.040
	8a, 100 mg/kg × 14 days, QD, SC (suspension)	0 ± 0.34 (0–2)	100%/33.3%	0.1207	9.30	NM	0.069
	8a, 300 mg/kg × 7 days, QD, SC (suspension)	0 ± 0 (0–0)	100%/100%	0.0208	7.85	10.6 (day 21)	0.48
						4.64 (day 42)
	8a, 100 mg/kg × 28 days, QD, PO (suspension)	20 ± 6.92 (5–50)	–135.3%/0%	0.999	0.210	0.006 (day 42)	0.003

^aNM = not measured. N/A = not applicable. Statistical significance was tested by Kruskal–Wallis followed by Dunn’s multiple comparisons test.